CAMRF News and Press, Camurus AB From 04/02/20

Large increase in the number of patients treated with weekly and monthly Buvidal ®  for opioid dependence Camurus reiterates its 2020 outlook, with sales and total revenues expected to reach the higher end of previous guidance   Lund, Sweden , April 2, 2020 /PRNews...

Ra Pharmaceuticals (NASDAQ: RARX ) inks a global license agreement with Camurus AB ( OTC:CAMRF ) securing the rights to the latter's FluidCrystal technology that will enable the development of a long-acting formulation of C5 inhibitor zilucoplan for the treatment of complement-mediated dis...

FluidCrystal® extended release formulation of zilucoplan achieved rapid and sustained pharmacodynamic inhibition of complement C5 in non-human primates, supporting at least once weekly dosing CAMBRIDGE, Massachusetts and LUND, Sweden , July 16, 2019 /PRNewswire/ -- Ra Pharmaceu...

LUND, Sweden , June 20, 2019 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX), a commercial stage biopharmaceutical company specializing in long-acting medicines for severe and chronic disorders, announced today the acceptance by the US Food and Drug Administration (FDA) of an Investigational N...

Camurus AB (publ) ( OTC:CAMRF ): Q1 GAAP EPS of -SEK1.50. More news on: Camurus AB (publ), Earnings news and commentary, Read more ...

STOCKHOLM , May 9, 2019 /PRNewswire/ -- "Initial sales of Buvidal® follows plan and we are expecting to see significant growth during the year" Summary first quarter 2019   Buvidal® launched as the first long-acting medicine for opioid dependence in the EU; with in...